These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 3909800

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Misonidazole combined with large-fraction pelvic irradiation in the treatment of patients with advanced pelvic malignancies. Preliminary report of an ongoing RTOG phase I-II study.
    Meoz RT, Spanos WJ, Doss L, Johnson R, Wasserman TH.
    Am J Clin Oncol; 1983 Aug; 6(4):417-22. PubMed ID: 6191560
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Misonidazole and unconventional radiation in advanced squamous cell carcinoma of the esophagus: a phase II study of the Radiation Therapy Oncology Group.
    Ydrach AA, Marcial VA, Parsons J, Concannon J, Asbell SO, George F.
    Int J Radiat Oncol Biol Phys; 1982 Aug; 8(3-4):357-9. PubMed ID: 6809704
    [Abstract] [Full Text] [Related]

  • 6. A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04).
    Lee DJ, Pajak TF, Stetz J, Order SE, Weissberg JB, Fischer JJ.
    Int J Radiat Oncol Biol Phys; 1989 Feb; 16(2):465-70. PubMed ID: 2646255
    [Abstract] [Full Text] [Related]

  • 7. Large fraction irradiation with or without misonidazole in advanced non-oat cell carcinoma of the lung: a phase III randomized trial of the RTOG. Radiation Therapy Oncology Group.
    Simpson JR, Bauer M, Wasserman TH, Perez CA, Emami B, Wiegensberg I, Zinninger M, Durbin LM.
    Int J Radiat Oncol Biol Phys; 1987 Jun; 13(6):861-7. PubMed ID: 3034841
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Once-a-week lower hemibody irradiation (HBI) for metastatic cancers.
    Nag S, Shah V.
    Int J Radiat Oncol Biol Phys; 1986 Jun; 12(6):1003-5. PubMed ID: 2424877
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Kinetic aspects of misonidazole and its major metabolite in radiotherapy.
    Meering PG, Gonzalez DG, Maes RA, van Peperzeel HA.
    Hum Toxicol; 1985 Jul; 4(4):425-34. PubMed ID: 4018823
    [Abstract] [Full Text] [Related]

  • 17. Radiation Therapy Oncology Group clinical trials with misonidazole.
    Wasserman TH, Stetz J, Phillips TL.
    Cancer; 1981 May 15; 47(10):2382-90. PubMed ID: 7023642
    [Abstract] [Full Text] [Related]

  • 18. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
    Phillips TL, Wasserman TH, Johnson RJ, Levin VA, VanRaalte G.
    Cancer; 1981 Oct 15; 48(8):1697-704. PubMed ID: 6269723
    [Abstract] [Full Text] [Related]

  • 19. Treatment of bladder carcinoma with irradiation combined with misonidazole.
    Papavasiliou C, Yiogarakis D, Davillas N, Seretakis L, Pappas J, Licourinas M, Theodorou C, Stathopoulos P, Katsoyianni C, Thanos A.
    Int J Radiat Oncol Biol Phys; 1983 Nov 15; 9(11):1631-3. PubMed ID: 6358156
    [Abstract] [Full Text] [Related]

  • 20. Protection by WR-2721 of human bone marrow function following irradiation.
    Constine LS, Zagars G, Rubin P, Kligerman M.
    Int J Radiat Oncol Biol Phys; 1986 Aug 15; 12(8):1505-8. PubMed ID: 2428794
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.